PL1934177T3 - Pochodne prolinoamidowe jako modulatory kanałów sodowych - Google Patents

Pochodne prolinoamidowe jako modulatory kanałów sodowych

Info

Publication number
PL1934177T3
PL1934177T3 PL06806110T PL06806110T PL1934177T3 PL 1934177 T3 PL1934177 T3 PL 1934177T3 PL 06806110 T PL06806110 T PL 06806110T PL 06806110 T PL06806110 T PL 06806110T PL 1934177 T3 PL1934177 T3 PL 1934177T3
Authority
PL
Poland
Prior art keywords
sodium channel
channel modulators
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
PL06806110T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Publication of PL1934177T3 publication Critical patent/PL1934177T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
PL06806110T 2005-10-10 2006-10-06 Pochodne prolinoamidowe jako modulatory kanałów sodowych PL1934177T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
EP06806110A EP1934177B8 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (1)

Publication Number Publication Date
PL1934177T3 true PL1934177T3 (pl) 2013-03-29

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06806110T PL1934177T3 (pl) 2005-10-10 2006-10-06 Pochodne prolinoamidowe jako modulatory kanałów sodowych

Country Status (20)

Country Link
US (2) US7655693B2 (pl)
EP (1) EP1934177B8 (pl)
JP (1) JP5139305B2 (pl)
KR (1) KR101282464B1 (pl)
AR (1) AR056575A1 (pl)
AT (1) ATE556049T1 (pl)
AU (1) AU2006301470B2 (pl)
BR (1) BRPI0616944B8 (pl)
CA (1) CA2625642C (pl)
CR (1) CR9898A (pl)
EA (1) EA015736B1 (pl)
ES (1) ES2387405T3 (pl)
IL (1) IL192627A0 (pl)
MA (1) MA29817B1 (pl)
NO (1) NO20082145L (pl)
NZ (1) NZ567051A (pl)
PE (1) PE20070592A1 (pl)
PL (1) PL1934177T3 (pl)
TW (1) TW200730494A (pl)
WO (1) WO2007042239A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
WO2011029762A1 (en) * 2009-09-14 2011-03-17 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
CA2936886A1 (en) 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
EP3237379B1 (en) * 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2018085521A2 (en) * 2016-11-02 2018-05-11 Biogen Inc. Novel dosage regimen
MA52458A (fr) * 2017-05-19 2021-03-10 Biogen Ma Inc Nouvelles formes cristallines
WO2019071162A2 (en) * 2017-10-05 2019-04-11 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
AU2018347349A1 (en) 2017-10-10 2020-04-23 Biogen Inc. Process for preparing spiro derivatives
KR20210002472A (ko) * 2018-04-16 2021-01-08 바이오젠 엠에이 인코포레이티드 신경병증성 통증을 치료하는 방법
JP2022527213A (ja) * 2019-04-10 2022-05-31 バイオジェン・エムエイ・インコーポレイテッド アルファ－カルボキサミドピロリジン誘導体を調製するためのプロセス
JP2022526431A (ja) * 2019-04-10 2022-05-24 バイオジェン インコーポレイテッド アルファ－カルボキサミドピロリジン誘導体を調製するためのプロセス
EP4096508A4 (en) * 2020-01-30 2024-03-27 Mohammad Javed COMBINATION THERAPIES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
AU782353B2 (en) 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
JP2006523701A (ja) * 2003-04-18 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2006119390A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
JP2008540443A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
EP1888549A2 (en) 2005-05-19 2008-02-20 Vertex Pharmaceuticals, Inc. Biaryls useful as modulators of ion channels
CA2621564C (en) * 2005-09-09 2014-06-03 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
PE20070592A1 (es) 2007-06-23
TW200730494A (en) 2007-08-16
IL192627A0 (en) 2011-08-01
EA015736B1 (ru) 2011-10-31
KR101282464B1 (ko) 2013-07-04
US7655693B2 (en) 2010-02-02
ES2387405T3 (es) 2012-09-21
NO20082145L (no) 2008-05-07
ATE556049T1 (de) 2012-05-15
CA2625642A1 (en) 2007-04-19
EP1934177B1 (en) 2012-05-02
JP2009511519A (ja) 2009-03-19
EA200801054A1 (ru) 2008-08-29
KR20080059296A (ko) 2008-06-26
CR9898A (es) 2008-07-29
AU2006301470B2 (en) 2012-06-14
AR056575A1 (es) 2007-10-10
BRPI0616944B1 (pt) 2020-04-14
CA2625642C (en) 2013-12-24
AU2006301470A1 (en) 2007-04-19
US8153681B2 (en) 2012-04-10
WO2007042239A1 (en) 2007-04-19
US20080280969A1 (en) 2008-11-13
NZ567051A (en) 2011-03-31
MA29817B1 (fr) 2008-09-01
EP1934177B8 (en) 2012-09-05
EP1934177A1 (en) 2008-06-25
BRPI0616944B8 (pt) 2021-05-25
US20100105754A1 (en) 2010-04-29
BRPI0616944A2 (pt) 2011-07-05
JP5139305B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
IL192627A0 (en) Prolinamide derivatives as sodium channel modulators
AP2516A (en) 2-Pyridine carboxamide derivatives as sodium channel modulators
IL178767A0 (en) Indolyl derivatives as liver - x - receptor modulators
IL184657A0 (en) Adam-9 modulators
GB0522477D0 (en) Modulator
EP2178373A4 (en) HETEROCYCLES AS COLD CHANNEL MODULATORS
IL193176A0 (en) Benzoyl-piperidine derivatives as 5ht2/d3 modulators
HK1124324A1 (en) 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
IL189846A0 (en) Theramutein modulators
EP1915162A4 (en) MODULATORS
EP2042152A4 (en) GEL COMPOSITION
GB0619102D0 (en) Seal
ZA200802879B (en) Prolinamide derivatives as sodium channel modulators
GB0507940D0 (en) Seal
ZA200806810B (en) Benzoyl-piperidine derivatives as 5HT2/D3 modulators
EP1915817A4 (en) DOUBLE PORT MODULATOR
GB0425187D0 (en) Improvements to seals
GB0613566D0 (en) Crystalline sodium atorvastatin
GB0502972D0 (en) Seals
ZA200802433B (en) Theramutein modulators
GB2440508B (en) Denture seal
AU2006902902A0 (en) Immunocytotoxity Modulating Composition
GB0406006D0 (en) Sodium channels
GB0406004D0 (en) Sodium channels
GB0406002D0 (en) Sodium channels